Ib bio lab report

During January 2017, AstraZeneca provided an update on its IO late-stage clinical development program in first-line NSCLC, including a refinement of the Phase III MYSTIC study. MYSTIC was initially designed to study the benefit of durvalumab monotherapy as well as durvalumab and tremelimumab (durva + treme) combination therapy compared to standard-of-care (SoC) chemotherapy, concentrated on progression-free survival (PFS). MYSTIC now is evaluating PFS and overall survival (OS) endpoints in patients with PDL1-expressing tumors for durvalumab monotherapy and the combination of durva + treme, as well as in “all comers” for the combination of durva + treme, versus SoC chemotherapy.

Ib bio lab report

ib bio lab report

Media:

ib bio lab reportib bio lab reportib bio lab reportib bio lab report